The collaborative vaccine to prevent COVID-19 will rely on Medicago's plant-based production platform to manufacture the vaccine’s antigen. Phase I clinical testing is expected to start in mid-July, with the companies planning to manufacture approximately 100m doses by the end of 2021. Quality is key when it comes to advancing clinical trials, which is why Yourway is committed to maintaining the highest standards, as evidenced by our pursuit of continuous improvement, modern facilities, and industry certifications.